The cell-type-specific genetic architecture of chronic pain in brain and dorsal root ganglia.

Summary

By integrating massive GWAS with single-cell transcriptomic and chromatin data, this study localizes chronic pain genetic risk to glutamatergic cortical circuits and a specific hDRG nociceptor subtype (hPEP.TRPV1/A1.2). It highlights pathways including kinase signaling, GABA synapses, and axon guidance, creating a mechanistic roadmap for targeted analgesic development.

Key Findings

• Pain-associated variants are enriched in glutamatergic neurons (prefrontal cortex, hippocampal CA1–3, amygdala).
• In human DRG, the hPEP.TRPV1/A1.2 neuronal subtype shows robust enrichment of pain risk.
• Chromatin accessibility implicates excitatory/inhibitory neocortical neurons and dorsal horn midventral neurons/OPCs.
• Gene-level heritability points to kinase activity, GABAergic synapses, axon guidance, and neuronal projection development.

Clinical Implications

Guides translational programs toward glutamatergic cortical circuits and hDRG TRPV1/A1.2 nociceptors, informing biomarker selection and cell-type–specific analgesic strategies.

Limitations

• Observational genetic associations cannot establish causality or druggability without experimental validation.
• Cross-species chromatin data (mouse dorsal horn) may limit direct translatability.

Future Directions

Validate prioritized cell types and pathways in functional models, develop cell-type–specific modulators, and design biomarker-driven clinical trials targeting identified circuits.